About CiMaas
CiMaas is a company based in Maastricht (Netherlands) founded in 2015 by Wilfred T V Germeraad and Gerard M J Bos was acquired by 819 Capital Partners in December 2024. CiMaas offers products and services including Adoptive NK Cell Therapy and Feeder Cell Technology. CiMaas operates in a competitive market with competitors including BeiGene, Moderna, Incyte, ALX Oncology and MorphoSys, among others.
- Headquarter Maastricht, Netherlands
- Founders Wilfred T V Germeraad, Gerard M J Bos
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
$312.9 K (USD), Grant
Jan 01, 2020
-
Investors
European Union
& 1 more
-
Employee Count
Not available
-
Acquired by
819 Capital Partners
(Dec 02, 2024)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of CiMaas
CiMaas offers a comprehensive portfolio of products and services, including Adoptive NK Cell Therapy and Feeder Cell Technology.
Therapy using NK cells to target and treat cancer patients effectively.
Technology for expanding and activating NK cells for clinical use.
Funding Insights of CiMaas
Investors in CiMaas
CiMaas has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include European Union and 819 Capital Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investment firm focused on venture capital and private equity.
|
Locked | Locked | Locked | |
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Locked | Locked | Locked |
Investor details for CiMaas
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by CiMaas
Investment portfolio details for CiMaas
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - CiMaas
Detailed financials for CiMaas
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cimaas Comparisons
Peer comparison for CiMaas
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of CiMaas
CiMaas operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BeiGene, Moderna, Incyte, ALX Oncology and MorphoSys, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
ALX Oncology is focused on advancing cancer treatment therapies.
|
|
| Locked | Locked | Locked |
Therapeutic antibodies for cancer and other diseases are developed.
|
|
| Locked | Locked | Locked |
mRNA therapeutics platform is provided for multi-functional treatments.
|
Detailed competitors of CiMaas
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cimaas
Complete news archive for CiMaas
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about CiMaas
CiMaas was founded in 2015 and raised its 1st funding round 5 years after it was founded.
CiMaas is headquartered in Maastricht, Netherlands. It is registered at Maastricht, Limburg, Netherlands.
Gerard M J Bos is the current CEO of CiMaas. They have also founded this company.
Founded in 2015 and based in Maastricht, Netherlands, focus is placed on the development of cancer immunotherapeutics within the biotechnology sector. Operations center on preclinical drug candidates, including CIM301 as a dendritic cell vaccine targeting lung cancer, CIM201 as an adoptive CAR-NK cell therapy for solid tumors, and CIM101 as an adoptive NK cell therapy for acute myeloid leukemia.
CiMaas's top competitors include Moderna, BeiGene and Strand Therapeutics.
CiMaas offers Adoptive NK Cell Therapy and Feeder Cell Technology.
CiMaas has 2 investors. Key investors include European Union, and 819 Capital Partners.